Replies to post #141509 on Biotech Values

[DewDiligence]

INHX claimed they were waiting on regulatory approval to test the 300mg. dose of INX-189 before they were bought by BMY. As I previously pointed out this was only posturing to draw in a bidder. It was clear to me this drug was borderline unsafe and BMY knew it just as well. They just didn't have any other options.

Quite plausible, IMO.

Any lack of potency testing INX-189 at lower therapeutic doses (in theory) could be overcome by the other classes of drugs within the combination.

Exactly. That’s why Sadeghi-Nejad’s arguments, although compelling (with the exception noted in #msg-75308953), are far from probative.